Drug Discovery Innovation 2019
Meet with Q2 Solutions and learn how we can accommodate your specific needs on a global scale
About This EventThe 5th DIA China Drug Discovery Innovation (DDI) Conference will be held in Shanghai, China. The conference brings key stakeholders, innovators and thought leaders together to exchange expertise, experience and opinions.
Be sure to meet Q2 Solutions at booths 11& 12 and plan to attend our Immuno-Oncology Scientific Symposium on October 24th as part of the overall DDI conference program. Our Symposium focuses on various I-O topics featuring six presentations with seven of Q2 Solutions' experts.
If attending the Pre-Conference Workshop, please join us during the “Best Integrated Translational Oncology” Workshop.
Pre-Conference Workshop details:
- Title: "How to Leverage your Central Laboratory Scientific Expertise for Biomarker Testing"
- Speaker: Dr. Patrice Hugo, Chief Scientific Officer
- Date and Time: Wednesday, October 23rd at 11:00 am
Immunology; Chief Scientific Officer
Dr. Patrice Hugo obtained his Ph.D. in Experimental Medicine/Immunology at McGill University and completed 5 years of post-doctoral fellowships in Immunology at the Walter Elisa Hall Institute in Australia, and at the Howard Hughes Medical Institute in Denver, Colorado. He then became a Principal Investigator leading the T-lymphocyte Unit at the Montreal Clinical Research Institute with academic appointments at McGill University and Montreal University. Throughout his academic work, Dr. Hugo focused on T-lymphocyte differentiation, self-tolerance induction, and leukemogenesis. He worked at PROCREA BioSciences and Caprion as Chief Scientific Officer and Executive Vice President R&D, respectively. Dr. Hugo was assigned as Chief Scientific Officer at Clearstone Central Laboratories later acquired by LabCorp and became Associate Vice President and Chief Scientist at LabCorp/Covance Central Laboratories Division. Dr. Patrice Hugo joined Q2 Solutions as Chief Scientific Officer where he currently leads the global scientific strategy and is responsible for the medical affairs and scientific activities of the Central Laboratories, and the Specialty Testing Centers of Excellence worldwide including Expression Analysis Genomics, Vaccine, Biomarkers and BioAnalytical/ADME laboratories. Dr. Hugo has more than 75 peer-reviewed scientific publications. He also played an active role in a number of industry organizations, including being a member of the Board of Directors for Personalized Medicine Partnership for Cancer in Quebec, and the Steering Committee for the Biomarker Factory. He is also a member of the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC).